Moderna announced that the U.S. Food and Drug Administration has approved mRESVIA, an mRNA respiratory syncytial virus vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna. “The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform,” said Stephane Bancel, Chief Executive Officer of Moderna. “mRESVIA protects older adults from the severe outcomes of RSV infection, and it is the only RSV vaccine available in a pre-filled syringe designed to maximize ease of administration, saving vaccinators’ time and reducing the risk of administrative errors. This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. With mRESVIA, we continue to deliver for patients by addressing global public health threats related to infectious diseases.”